Rheumatoid arthritis (RA) is an autoimmune disease. The immune system mistakenly attacks the lining of the joints, called the synovium, causing chronic inflammation that leads to pain, swelling, and progressive joint damage. Unlike osteoarthritis, which results from physical wear and tear on cartilage, RA is driven by a malfunctioning immune system that treats healthy joint tissue as a threat.
How the Immune System Attacks the Joints
In a healthy body, the immune system produces antibodies that target bacteria, viruses, and other invaders. In RA, the immune system produces abnormal antibodies called autoantibodies that target healthy tissues instead. Two autoantibodies are central to the disease: rheumatoid factor (RF) and anti-CCP antibodies. Anti-CCP antibodies are found in most people with RA and are almost never found in people without it, making them highly specific to the disease (95 to 98% diagnostic specificity). Rheumatoid factor is less precise. It can show up in other autoimmune conditions and even in some healthy people, which is why doctors typically test for both.
The inflammation centers on the synovium, a thin membrane that lines the inside of joints and produces fluid to keep them lubricated. When the immune system attacks this membrane, it thickens and swells. Over time, the inflamed synovium invades and erodes the surrounding cartilage and bone. This erosion can begin within the first two years of the disease and continues to progress without treatment. Immune cells, including certain white blood cells called neutrophils and macrophages, accumulate in the joint lining and amplify the damage by releasing inflammatory molecules.
Recent research has even identified specialized cells circulating in the blood, called pre-inflammatory mesenchymal cells, that carry a signature matching the cells in inflamed joint tissue. These cells appear about one week before a disease flare, suggesting they are recruited to the joints and help reignite inflammation. This finding reinforces just how actively the immune system drives the disease rather than inflammation being a passive side effect.
What Triggers the Autoimmune Response
No single cause has been identified, but RA results from a combination of genetic susceptibility and environmental triggers. Heritability is estimated at about 60%, meaning genetics play a substantial role. The strongest genetic risk factor is a set of gene variations in a region called HLA-DRB1, often referred to as the “shared epitope.” These gene variants affect how the immune system identifies threats, and they influence the intensity and diversity of the autoantibody response.
Among environmental triggers, smoking is the most well-established. It increases RA risk through multiple pathways, some linked to the shared epitope gene and some independent of it. In people who carry the genetic risk factor, smoking appears to amplify the production of anti-CCP antibodies, essentially pouring fuel on a genetic predisposition. But even in people without the genetic risk factor, smoking still raises the likelihood of developing certain subtypes of RA. Other suspected triggers include infections, hormonal changes, and gum disease, though none have the same weight of evidence as smoking.
RA vs. Osteoarthritis
The confusion between rheumatoid arthritis and osteoarthritis is common because both cause joint pain and stiffness. But they are fundamentally different diseases. Osteoarthritis is a degenerative condition where the cartilage cushioning the ends of bones gradually wears down, usually from aging, repetitive use, or prior injury. There is no immune system malfunction involved.
RA, by contrast, starts with immune-driven inflammation in the joint lining. It tends to affect joints symmetrically (both hands, both knees), while osteoarthritis often affects joints unevenly or on one side. RA also commonly causes systemic symptoms like fatigue, low-grade fever, and general malaise, because the immune dysfunction is not limited to the joints. Osteoarthritis is a local, mechanical problem. RA is a systemic, immune-mediated one.
Effects Beyond the Joints
Because RA is a systemic autoimmune disease, the inflammation it generates can reach well beyond the joints. Roughly a quarter to a third of people with RA develop what are called extra-articular manifestations, meaning the disease affects other organs. The most significant include:
- Lungs: RA can cause interstitial lung disease (scarring of lung tissue), inflammation of the lining around the lungs, airway disease, and in rare cases, pulmonary hypertension.
- Heart: Chronic systemic inflammation accelerates cardiovascular disease, increasing the risk of heart attack and stroke.
- Eyes: Inflammatory eye conditions, including dryness and scleritis (inflammation of the white of the eye), are relatively common.
- Skin: Firm lumps called rheumatoid nodules can form under the skin, typically near pressure points like the elbows.
- Blood vessels: In severe cases, vasculitis (inflammation of blood vessels) can develop, potentially affecting blood flow to organs and tissues.
These complications underscore that RA is not simply “joint pain.” The same immune dysfunction damaging the synovium generates widespread inflammation that puts multiple organ systems at risk over time.
How Treatment Targets the Immune System
Because RA is autoimmune in nature, the most effective treatments work by suppressing or modulating the immune system rather than just relieving pain. These medications are called disease-modifying antirheumatic drugs, or DMARDs, and they come in two broad categories.
Traditional DMARDs work by broadly dampening immune system activity. They slow the overall immune response enough to reduce joint inflammation and prevent erosion from progressing. Most people with RA start on one of these medications soon after diagnosis, and the earlier treatment begins, the better the outcomes. Bone erosion and cartilage destruction can start within the first two years, so there is a real urgency to controlling the immune response before irreversible damage sets in.
Biologic DMARDs are more targeted. They are engineered proteins designed to block specific components of the immune response. Some block a key inflammatory signaling molecule called tumor necrosis factor. Others target specific types of immune cells, like T-cells or B-cells, that play direct roles in attacking joint tissue. A newer class of targeted medications works by interfering with specific signaling pathways inside immune cells, effectively cutting off the communication chain that triggers inflammation. These options give doctors the ability to fine-tune treatment based on which part of the immune system is most active in a given patient.
Living With RA and Remission
With current treatments, remission is a realistic goal for many people with RA, especially those diagnosed and treated early. Remission in RA does not mean the disease is cured. It means the immune-driven inflammation is controlled well enough that joint damage stops progressing and symptoms are minimal or absent. Most people in remission continue taking medication to keep the immune system in check.
Globally, about 18 million people were living with RA as of 2019. The disease is two to three times more common in women than men and most often begins between the ages of 30 and 60, though it can start at any age. The gap in prevalence between women and men points to a likely role for hormonal factors in triggering or sustaining the autoimmune process, though the exact mechanism is still being studied.
The practical reality of RA is that early, aggressive treatment makes a significant difference. People who begin immune-targeting therapy within months of symptom onset have substantially better long-term joint function than those who wait. If you have persistent joint swelling, morning stiffness lasting more than 30 minutes, or symmetrical joint pain, blood tests for anti-CCP antibodies and rheumatoid factor can help clarify whether an autoimmune process is driving your symptoms.